| 摘要 |
The compound of formula I wherein X is 0, S, N-CH3, CH=CH or CAlk = CAlk, where the Alk are independently (C1-4)alkyl R1 and R2 are independently hydrogen, halogen, (C1-4)alkyl, (C1-4)alkoxy or trifluoromethyl Het is a radical having one of the formulae of (a) to (p) wherein: R3 and R8 are independently hydrogen or (C1-4)alkyl, R4 is hydrogen, (C1-4)alkyl, cyano, nitro, formyl or (C1- 4)alkylcarbonyl R5 and R6 are independently hydrogen, (C1-7)alkyl, (C3- 7)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, (C1-4)alkoxy(C2-5)alkyl or benzyl R7 is hydrogen, hydroxy, (C1-4)alkyl or (C1-4)alkoxy, W is N, C-CN, C-NO2, C-COH or C-CO-Alk: where Alk is as defined above X is as defined above in a free base or acid addition salt form and a process for the preparation of the compound is described. A pharmaceutical composition comprising the compound of formula I is useful for the treatment of any state with increased level of CRF (corticotropine releasing factor) or of a disease induced or facilitated by CRF or a state in which the HPA (hypothalamic pituitary axis) is disregulated.
|
